Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms

[1]  A. Korczyn,et al.  Quality of life in Parkinson's disease: A gender‐specific perspective , 2019, Acta neurologica Scandinavica.

[2]  G. Mazzoccoli,et al.  Parkin Mutation Affects Clock Gene-Dependent Energy Metabolism , 2019, International journal of molecular sciences.

[3]  M. Taghizadeh,et al.  Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. , 2019, Clinical nutrition.

[4]  R. Reiter,et al.  Melatonin and pancreatic cancer: Current knowledge and future perspectives , 2018, Journal of cellular physiology.

[5]  R. Reiter,et al.  Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives , 2018, Journal of cellular physiology.

[6]  M. Ramkumar,et al.  Antiapoptotic role of Agaricus blazei extract in rodent model of Parkinson's disease. , 2019, Frontiers in bioscience.

[7]  F. Blandini,et al.  Role of Autophagy in Parkinson's Disease. , 2019, Current medicinal chemistry.

[8]  R. Richardson,et al.  Melatonin Treatment of Visual Hallucinations in Parkinson Disease. , 2018, Journal of clinical psychopharmacology.

[9]  I. Calou,et al.  Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats , 2018, Journal of neuroinflammation.

[10]  Baogang Xie,et al.  Melatonin attenuates hLRRK2-induced long-term memory deficit in a Drosophila model of Parkinson's disease. , 2018, Biomedical reports.

[11]  Fen Wang,et al.  Disruption of the Circadian Clock Alters Antioxidative Defense via the SIRT1-BMAL1 Pathway in 6-OHDA-Induced Models of Parkinson's Disease , 2018, Oxidative medicine and cellular longevity.

[12]  M. H. Barros,et al.  Melatonin improves survival and respiratory activity of yeast cells challenged by alpha‐synuclein and menadione , 2018, Yeast.

[13]  T. Manivasagam,et al.  Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson's disease , 2018, Life sciences.

[14]  Beatriz I Fernandez-Gil,et al.  Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases , 2017, PloS one.

[15]  Tadeusz Sarna,et al.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease , 2017, Progress in Neurobiology.

[16]  S. Vollstaedt-Klein,et al.  The association of pineal gland volume and body mass in obese and normal weight individuals: a pilot study. , 2016, Psychiatria Danubina.

[17]  Pei-Chun Chen,et al.  Melatonin prevents the dynamin‐related protein 1‐dependent mitochondrial fission and oxidative insult in the cortical neurons after 1‐methyl‐4‐phenylpyridinium treatment , 2016, Journal of pineal research.

[18]  M. Taghizadeh,et al.  Combined Administration of Melissa officinalis and Boswellia serrata Extracts in an Animal Model of Memory , 2016, Iranian journal of psychiatry and behavioral sciences.

[19]  Ana Guerra-Librero,et al.  Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ‐1/MUL1 network , 2016, Journal of pineal research.

[20]  R. Reiter,et al.  On the significance of an alternate pathway of melatonin synthesis via 5‐methoxytryptamine: comparisons across species , 2016, Journal of pineal research.

[21]  Jennifer R. Rider,et al.  Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men , 2016, Journal of biological rhythms.

[22]  C. Ross,et al.  Melatonin attenuates hLRRK2-induced sleep disturbances and synaptic dysfunction in a Drosophila model of Parkinson's disease. , 2016, Molecular medicine reports.

[23]  R. Barker,et al.  Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[24]  G. Mazzoccoli,et al.  Morphofunctional and signaling molecules overlap of the pineal gland and thymus: role and significance in aging , 2016, Oncotarget.

[25]  E. Unlu,et al.  Assessment of Pineal Gland Volume and Calcification in Healthy Subjects: Is it Related to Aging? , 2016, Journal of the Belgian Society of Radiology.

[26]  I. Barshack,et al.  Melatonin prevents kidney injury in a high salt diet‐induced hypertension model by decreasing oxidative stress , 2016, Journal of pineal research.

[27]  P. Chan,et al.  Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese , 2015, Scientific Reports.

[28]  J. Correale,et al.  Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses , 2015, Cell.

[29]  Hao Li,et al.  Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation , 2015, Autophagy.

[30]  K. Mohanakumar,et al.  Melatonin enhances L‐DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced parkinsonism in mice , 2015, Journal of pineal research.

[31]  G. Tanriover,et al.  Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model , 2015, Free radical research.

[32]  Ushodaya Mattam,et al.  Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson’s disease male Wistar rat model and effect of melatonin administration , 2015, Biogerontology.

[33]  G. Tanriover,et al.  Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease , 2014, Neurochemistry International.

[34]  R. Reiter,et al.  Melatonin identified in meats and other food stuffs: potentially nutritional impact , 2014, Journal of pineal research.

[35]  L. Haddad,et al.  Pineal gland volume in primary insomnia and healthy controls: a magnetic resonance imaging study , 2014, Journal of sleep research.

[36]  R. Barker,et al.  Sleep and circadian rhythm regulation in early Parkinson disease. , 2014, JAMA neurology.

[37]  A. Lang,et al.  Pharmacological treatment of Parkinson disease: a review. , 2014, JAMA.

[38]  C. Niu,et al.  Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation , 2014, Neurological Sciences.

[39]  T. Manivasagam,et al.  Melatonin synergizes with low doses of L‐DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism , 2013, Journal of pineal research.

[40]  G. Ortiz,et al.  Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine , 2013, Metabolic Brain Disease.

[41]  D. Gao,et al.  NF-κB p65/p52 plays a role in GDNF up-regulating Bcl-2 and Bcl-w expression in 6-OHDA-induced apoptosis of MN9D cell , 2013, The International journal of neuroscience.

[42]  V. Baekelandt,et al.  Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein. , 2013, Histology and histopathology.

[43]  S. Hill,et al.  Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth. , 2013, Current aging science.

[44]  A. Domínguez-Rodríguez.  Melatonin in cardiovascular disease , 2012, Expert Opinion on Investigational Drugs.

[45]  Pravir Kumar,et al.  Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat , 2012, Neuroscience.

[46]  M. Raggi,et al.  Content of melatonin and other antioxidants in grape‐related foodstuffs: measurement using a MEPS‐HPLC‐F method , 2012, Journal of pineal research.

[47]  Ju-Young Kim,et al.  Melatonin improves inflammatory cytokine profiles in lung inflammation associated with sleep deprivation. , 2012, Molecular medicine reports.

[48]  R. Reiter,et al.  Melatonin membrane receptors in peripheral tissues: Distribution and functions , 2012, Molecular and Cellular Endocrinology.

[49]  Hsin-Chen Lee,et al.  Melatonin attenuates kainic acid‐induced neurotoxicity in mouse hippocampus via inhibition of autophagy and α‐synuclein aggregation , 2012, Journal of pineal research.

[50]  F. Moradi,et al.  Curcumin has Neuroprotection Effect on Homocysteine Rat Model of Parkinson , 2012, Journal of Molecular Neuroscience.

[51]  R. Reiter,et al.  Melatonin and cardiovascular disease: myth or reality? , 2012, Revista espanola de cardiologia.

[52]  Laurence Negre-Pages,et al.  Oro‐buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort , 2012, European journal of neurology.

[53]  G. Patki,et al.  Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease , 2011, Pharmacology Biochemistry and Behavior.

[54]  R. Reiter,et al.  Melatonin as a natural ally against oxidative stress: a physicochemical examination , 2011, Journal of pineal research.

[55]  B. Bloem,et al.  Reproducibility and validity of patient-rated assessment of speech, swallowing, and saliva control in Parkinson's disease. , 2011, Archives of physical medicine and rehabilitation.

[56]  J. Pariente,et al.  Role of melatonin on diabetes-related metabolic disorders. , 2011, World journal of diabetes.

[57]  David R. Williams,et al.  α-Synuclein in Parkinson disease and other neurodegenerative disorders , 2011, Clinical chemistry and laboratory medicine.

[58]  C. Tanner,et al.  Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.

[59]  M. Navarro-Alarcón,et al.  Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats , 2010, Journal of pineal research.

[60]  S. Jain,et al.  Melatonin or silymarin reduces maneb‐ and paraquat‐induced Parkinson’s disease phenotype in the mouse , 2010, Journal of pineal research.

[61]  G. Meredith,et al.  MPTP mouse models of Parkinson's disease: an update. , 2011, Journal of Parkinson's disease.

[62]  D. Kunz,et al.  A two‐part, double‐blind, placebo‐controlled trial of exogenous melatonin in REM sleep behaviour disorder , 2010, Journal of sleep research.

[63]  M. Kaneki,et al.  Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. , 2010, Biochemical and biophysical research communications.

[64]  Q. Tian,et al.  Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A , 2010, Alzheimer's & Dementia.

[65]  R. Sothern,et al.  Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease , 2010, European journal of neurology.

[66]  D. Skene,et al.  Physiology and pharmacology of melatonin in relation to biological rhythms , 2009, Pharmacological reports : PR.

[67]  Sang-H Choi,et al.  The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. , 2009, Trends in pharmacological sciences.

[68]  Nicola Simola,et al.  The 6-Hydroxydopamine model of parkinson’s disease , 2007, Neurotoxicity Research.

[69]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[70]  O. Suchowersky,et al.  Neuropathy as a potential complication of levodopa use in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[71]  C. Chi,et al.  Involvement of oxidative stress-activated JNK signaling in the methamphetamine-induced cell death of human SH-SY5Y cells. , 2008, Toxicology.

[72]  Nuria Llecha,et al.  6‐Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK‐mediated, p53‐independent activation of Bax and PUMA , 2008, Journal of neurochemistry.

[73]  J. Chuang,et al.  Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone‐induced parkinsonian rats , 2008, Journal of pineal research.

[74]  Shuwei Liu,et al.  d-β-hydroxybutyrate inhibits the apoptosis of PC12 cells induced by 6-OHDA in relation to up-regulating the ratio of Bcl-2/Bax mRNA , 2007, Autonomic Neuroscience.

[75]  P. Barone,et al.  Apoptotic mechanisms in mutant LRRK2-mediated cell death. , 2007, Human molecular genetics.

[76]  K. Mohanakumar,et al.  Melatonin protects against rotenone‐induced oxidative stress in a hemiparkinsonian rat model , 2007, Journal of pineal research.

[77]  S. Przedborski,et al.  Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.

[78]  Marwa A. Ahmed,et al.  Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model , 2006, International journal of experimental pathology.

[79]  M. Dubocovich,et al.  Functional MT1 and MT2 melatonin receptors in mammals , 2005, Endocrine.

[80]  Mark Stacy,et al.  Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson’s Disease , 2007, CNS drugs.

[81]  C. Medeiros,et al.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease , 2007, Journal of Neurology.

[82]  F. Torrealba,et al.  Maternal melatonin effects on clock gene expression in a nonhuman primate fetus. , 2006, Endocrinology.

[83]  Josephine Arendt,et al.  Human circadian rhythms: physiological and therapeutic relevance of light and melatonin , 2006, Annals of clinical biochemistry.

[84]  R. Reiter,et al.  The modulatory role of melatonin on immune responsiveness. , 2006, Current opinion in investigational drugs.

[85]  J. Muñoz-Castañeda,et al.  Melatonin reduces apoptosis and necrosis induced by ischemia/reperfusion injury of the pancreas , 2006, Journal of pineal research.

[86]  M. Pallàs,et al.  Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease , 2006, Journal of pineal research.

[87]  D. Malińska,et al.  Melatonin attenuates diabetes‐induced oxidative stress in rabbits , 2006, Journal of pineal research.

[88]  Jian-Zhi Wang,et al.  Role of melatonin in Alzheimer-like neurodegeneration , 2006, Acta Pharmacologica Sinica.

[89]  C. A. Froelich,et al.  Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. , 2005, Journal of molecular biology.

[90]  Glenna A Dowling,et al.  Melatonin for sleep disturbances in Parkinson's disease. , 2005, Sleep medicine.

[91]  Ximing Xu,et al.  Melatonin Reduces Inflammatory Injury Through Inhibiting NF-κB Activation in Rats With Colitis , 2005, Mediators of inflammation.

[92]  F. Sun,et al.  Melatonin protects against MPTP/MPP+‐induced mitochondrial DNA oxidative damage in vivo and in vitro , 2005, Journal of pineal research.

[93]  D. Weaver,et al.  Melatonin Plays a Crucial Role in the Regulation of Rhythmic Clock Gene Expression in the Mouse Pars Tuberalis , 2005, Annals of the New York Academy of Sciences.

[94]  D. Swaab,et al.  The human pineal gland and melatonin in aging and Alzheimer's disease , 2005, Journal of pineal research.

[95]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[96]  古谷 剛.  Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2005 .

[97]  Jian-Zhi Wang,et al.  Role of melatonin in Alzheimer-like neurodegeneration 1 , 2005 .

[98]  B. Thanvi,et al.  Long term motor complications of levodopa: clinical features, mechanisms, and management strategies , 2004, Postgraduate Medical Journal.

[99]  Hideki Hayakawa,et al.  Caspase-11 Mediates Inflammatory Dopaminergic Cell Death in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson's Disease , 2004, The Journal of Neuroscience.

[100]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[101]  K. Mohanakumar,et al.  Melatonin protects against oxidative stress caused by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the mouse nigrostriatum , 2004, Journal of pineal research.

[102]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[103]  K. Heidenreich,et al.  The pesticide rotenone induces caspase‐3‐mediated apoptosis in ventral mesencephalic dopaminergic neurons , 2003, Journal of neurochemistry.

[104]  M. Cataldi,et al.  Apoptosis induced in neuronal cells by oxidative stress: role played by caspases and intracellular calcium ions. , 2003, Toxicology letters.

[105]  R. Reiter,et al.  Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin , 2003, Journal of pineal research.

[106]  F. Herrera,et al.  Protective effect of melatonin in a chronic experimental model of Parkinson’s disease , 2002, Brain Research.

[107]  J. Chuang,et al.  Melatonin attenuates MPP+‐induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway , 2002, Journal of pineal research.

[108]  R. Reiter,et al.  Melatonin in plants. , 2009, Nutrition reviews.

[109]  M. Beal,et al.  Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease , 2001, The Journal of Neuroscience.

[110]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[111]  J. Uney,et al.  Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[112]  H. Berendse,et al.  Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell , 2001, Annals of neurology.

[113]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[114]  A. Granholm,et al.  Time course of degenerative alterations in nigral dopaminergic neurons following a 6‐hydroxydopamine lesion , 2000, The Journal of comparative neurology.

[115]  R. Reiter,et al.  Actions of Melatonin in the Reduction of Oxidative Stress , 2000, Journal of Biomedical Science.

[116]  A. Davies,et al.  Induction of neuronal death by α‐synuclein , 2000, The European journal of neuroscience.

[117]  C. Moore,et al.  Effects of lighting conditions and melatonin supplementation on the cellular and humoral immune responses in Japanese quail Coturnix coturnix japonica. , 2000, General and comparative endocrinology.

[118]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[119]  W. Herrmann,et al.  A New Concept for Melatonin Deficit: On Pineal Calcification and Melatonin Excretion , 1999, Neuropsychopharmacology.

[120]  D. Neill,et al.  Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments , 1998, FEBS letters.

[121]  N. Rothwell,et al.  Caspases Mediate 6‐Hydroxydopamine‐Induced Apoptosis but Not Necrosis in PC12 Cells , 1998, Journal of neurochemistry.

[122]  K. S. Yoon,et al.  Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats , 1998, Neuroscience Letters.

[123]  M. M. Esteban,et al.  Melatonin prevents apoptosis induced by 6‐hydroxydopamine in neuronal cells: Implications for Parkinson's disease , 1998, Journal of pineal research.

[124]  S. Reppert.  Melatonin Receptors: Molecular Biology of a New Family of G Protein-Coupled Receptors , 1997, Journal of biological rhythms.

[125]  A. Benabid,et al.  p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells , 1997, Brain Research.

[126]  R. Reiter,et al.  Melatonin is protective against MPTP-induced striatal and hippocampal lesions. , 1996, Life sciences.

[127]  F. Xu,et al.  [Melatonin and aging]. , 1997, Sheng li ke xue jin zhan [Progress in physiology].

[128]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[129]  R. Reiter,et al.  Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. , 1995, Biochemistry and molecular biology international.

[130]  M. Schemper,et al.  Alterations in nocturnal serum melatonin levels in humans with growth and aging. , 1988, The Journal of clinical endocrinology and metabolism.

[131]  A. Lerner,et al.  ISOLATION OF MELATONIN, THE PINEAL GLAND FACTOR THAT LIGHTENS MELANOCYTES1 , 1958 .